Anavex Life Sciences Corp. director Axel Paeger filed a Form 4 on November 6, 2026, disclosing the acquisition of 50,000 stock options in the company traded on NASDAQ:AVXL, with a transaction date of November 3, 2026.

Key Highlights

  • Reporting person: Axel Paeger, identified as a Director of Anavex Life Sciences Corp.
  • Transaction: Acquisition (Code A) of 50,000 stock options (right to buy) on November 3, 2026.
  • Exercise price: $1.20 per share, with the price of the derivative security listed as $0.
  • Expiration date: November 2, 2036.
  • Vesting schedule: Options vest in three substantially equal annual installments beginning on March 31, 2027.
  • Resulting holdings: 50,000 derivative securities beneficially owned following the reported transaction, held directly.

Director Axel Paeger Acquires Stock Options in Anavex Life Sciences

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 6, 2026, Axel Paeger, a director of Anavex Life Sciences Corp. (NASDAQ:AVXL), acquired 50,000 stock options on November 3, 2026. The options carry an exercise price of $1.20 and are classified as a right to buy common stock. The underlying security is common stock, with 50,000 shares underlying the derivative.

The filing discloses that the options have an expiration date of November 2, 2036, and are priced at $0 at the time of acquisition. Per the explanation of responses included in the filing, "The option vests in three substantially sustainably equal annual installments beginning on March 31, 2027." Following this transaction, Paeger beneficially owns 50,000 derivative securities directly, with no non-derivative securities reported in Table I of the filing.

The Form 4 was signed by Sandra Boenisch as attorney-in-fact for Axel Paeger on November 6, 2026, pursuant to a Power of Attorney listed as Exhibit 24. No amendment date was indicated, and the filing was made by one reporting person. No Rule 10b5-1(c) plan box was checked in connection with this transaction.

What Was Disclosed

Anavex Life Sciences Corp. director Axel Paeger disclosed the acquisition of 50,000 stock options at an exercise price of $1.20, expiring November 2, 2036, vesting in three substantially equal annual installments starting March 31, 2027, as reported in a Form 4 filed November 6, 2026.